- Home
- AVTX vs INFQ.WS Comparison
AVTX vs INFQ.WS Comparison
Compare AVTX & INFQ.WS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$7.81
INFQ.WS
Infleqtion Inc. Warrants each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share
Current Price
$3.36
Company Overview
Basic Information| Metric | AVTX | INFQ.WS |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 710.1M | 649.0M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | AVTX | INFQ.WS |
|---|---|---|
| Price | $7.81 | $3.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $34.80 | N/A |
| AVG Volume (30 Days) | ★ 2.9M | 36.5K |
| Earning Date | 11-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,813,137.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2312.27 | N/A |
| 52 Week Low | $6.53 | $3.35 |
| 52 Week High | $24.27 | $4.03 |
Technical Indicators
Market Signals| Indicator | AVTX | INFQ.WS |
|---|---|---|
| Relative Strength Index (RSI) | 38.51 | N/A |
| Support Level | $6.53 | N/A |
| Resistance Level | $20.54 | N/A |
| Average True Range (ATR) | 0.62 | 0.00 |
| MACD | 0.36 | 0.00 |
| Stochastic Oscillator | 62.35 | 0.00 |
Price Performance
Historical Comparison AVTX
INFQ.WS
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.